RaQualia Pharma (TSE:4579) Total Stockholders Equity: 円7,831 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4579 RaQualia Pharma Inc TSE:4579
58 GF Score
Price 円542.00
GF Value 円840.17
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is RaQualia Pharma Total Stockholders Equity?

RaQualia Pharma TSE:4579 -1.99% 58 Total Stockholders Equity is 円7,831 Mil as of Jun. 2026. GuruFocus rates TSE:4579 with a GF Score™ of 58/100 and a GF Value™ of 円840.17 (Significantly Undervalued). The stock has 2 warning signs investors should review.

RaQualia Pharma's Total Stockholders Equity for the quarter that ended in Jun. 2026 was 円7,831 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. RaQualia Pharma's Book Value per Share for the quarter that ended in Jun. 2026 was 円300.83. The ratio of a company's debt over equity can be used to measure how leveraged this company is. RaQualia Pharma's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.34.

RaQualia Pharma  (TSE:4579) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

RaQualia Pharma's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(7830.909-0)/26.031
=300.83

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

RaQualia Pharma's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(607.861 + 2078.168) / 7830.909
=0.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Total Stockholders Equity Related Terms

RaQualia Pharma Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Total Stockholders Equity Chart

RaQualia Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4,788.00 5,496.98 6,120.44 5,570.51 6,896.26

RaQualia Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6,286.93 6,042.38 6,896.26 8,086.70 7,830.91
TSE:4579
58GF Score
RaQualia Pharma Inc TSE:4579
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of 円7,831 Mil mean?
RaQualia Pharma (TSE:4579) has a Total Stockholders Equity of 円7,831 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for RaQualia Pharma and its competitors.
Is RaQualia Pharma's Total Stockholders Equity too high?
RaQualia Pharma's current Total Stockholders Equity is 円7,831 Mil. Overall, RaQualia Pharma has a GF Score™ of 58/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Total Stockholders Equity compare to VRTX and REGN?
RaQualia Pharma's Total Stockholders Equity of 円7,831 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for RaQualia Pharma and its competitors. RaQualia Pharma's current Total Stockholders Equity is 円7,831 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円840.17, compared to a current price of 円542.00 — trading 35.5% below its estimated fair value. The current Total Stockholders Equity is 円7,831 Mil. RaQualia Pharma's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Total Stockholders Equity is 円7,831 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued. The current stock price of 円542.00 is trading 35.5% below its estimated GF Value™ of 円840.17. GuruFocus considers RaQualia Pharma to be Significantly Undervalued.

Key valuation signals for TSE:4579:

  • Total Stockholders Equity: 円7,831 Mil
  • GF Value™: 円840.17 vs. price of 円542.00 (35.5% below fair value)
  • GF Score™: 58/100 with 2 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
58GF Score

Get the complete analysis for TSE:4579

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円542.00
Price
円840.17
GF Value